X

All News

All News


Study Finds Ixabepilone Plus Bevacizumab Active in Platinum-Resistant or Recurrent Ovarian Cancer

The addition of bevacizumab to ixabepilone could be a promising treatment strategy for a group of patients with cancer currently lacking therapeutic options, according to data presented during the

The ASCO Post
05/12/2021
Addition of Celecoxib to Standard Adjuvant Therapy in Stage III Colon Cancer

The phase III CALGB/SWOG 80702 trial has shown no DFS benefit with the addition of the cyclooxygenase 2 inhibitor celecoxib to standard adjuvant therapy in patients with stage III colon cancer.

The ASCO Post
05/13/2021
Carnosol Is a Novel Inhibitor of p300 Acetyltransferase in Breast Cancer

Study investigators report that carnosol induces histone hypoacetylation in MDA-MB-231 and Hs578T breast cancer cells.

Frontiers in Oncology
05/13/2021

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39

Content Feed

Stage IV PD-L1–High Non–Small Cell Lung Cancer: Immunotherapy Alone or With Chemotherapy?

Except in patients with no smoking history, the addition of CT to immunotherapy does not add benefit as a first-line treatment in patients with stage IV nonsquamous NSCLC and high expression of PD-

The ASCO Post
05/12/2021
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer

This study aims to answer the question do older and/or frail patients with advanced gastroesophageal cancer benefit from less intensive palliative CT, and can a formal geriatric assessment assist..

JAMA Oncology
05/13/2021
Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Patients with mUC who progress on platinum-based combination chemotherapy and CPIs have limited options that offer objective response rates of approximately 10% with a median OS of 7-8 months.

Journal of Clinical Oncology
04/30/2021
Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells

Using originally designed BTK PROTAC compounds, study investigators show efficient BTK degradation in chronic lymphocytic leukemia cells.

Frontiers in Oncology
05/13/2021
Esophageal Cancer: Preop Chemoradiotherapy Benefit for 10 Years

Among patients with locally advanced resectable esophageal or junctional cancer, the overall survival benefit conferred by preoperative chemoradiotherapy persists for at least 10 years.

Medscape
05/13/2021
Possible Obesity Effect Detected in Cancer Death Rates

The obesity epidemic in the United States may be slowing improvements in cancer mortality, according to a new analysis of over 50 million cancer and heart disease deaths.

Medscape
05/10/2021
Rivaroxaban May Be Clinically Superior to LMWH in Patients With Cancer-Associated Thrombosis

Among patients with cancer-associated thrombosis, rivaroxaban may be superior to low-molecular-weight heparin for reducing all-cause mortality, although additional study is necessary...

Cancer Therapy Advisor
04/13/2021
Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response in Resectable NSCLC

Neoadjuvant CT with nivolumab plus platinum-doublet chemotherapy significantly improves pathologic complete response rates compared with CT alone in patients with resectable stage IB to IIIA NSCLC.

The ASCO Post
05/10/2021
Early-Onset Colorectal Cancer — Are Sugary Drinks to Blame?

High consumption of sugar-sweetened beverages in adolescence and young adulthood could partially explain the recent rapid rise in EO-CRC—at least in women, according to the authors...

Medscape
05/07/2021
Understanding Socioeconomic Disparities in Lung Cancer Care

A recent study finds that sociodemographic factors such as race, marital, income, and insurance status are associated with disparities in the receipt of lung cancer treatment, per findings...

Oncology Times - Latest Articles
04/01/2021
Pembrolizumab Plus Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Given each drug's single agent activity and unique mechanism of action, this study aims to evaluate the anti-tumour activity of PD-1 blockade with EGFR inhibition in recurrent or metastatic HNSCC.<

The Lancet Oncology
05/11/2021
Primary Breast Tumors Often Switch HER2 Status on Relapse

A substantial proportion of primary breast tumors that are HER2 negative (HER2-0) switch to showing HER2-low expression upon relapse, a first-of-its-kind study suggests.

Medscape
05/11/2021
Hepatic Metastasis in Newly Diagnosed Esophageal Cancer

The primary objective of this study is to explore the predictors of esophageal cancer with hepatic metastasis at the time of diagnosis. 

Frontiers in Oncology
05/10/2021
Surveillance Protocol and Early Cancer Detection in Patients With Constitutional Mismatch Repair Deficiency Syndrome

Use of an IRRDC surveillance protocol is associated with improved OS among patients with CMMRD, a cancer predisposition syndrome associated with inheritance of biallelic pathogenic variants in mism

The ASCO Post
05/11/2021
Evolution to HER2-Low Breast Cancer: Investigating Potential Therapeutics

The finding that breast tumors can evolve to express low HER2 potentially increases the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate t

The ASCO Post
05/11/2021
Radiation Therapy for Chemotherapy Refractory Gingival Myeloid Sarcoma

Study investigators present a single institution retrospective observational study of adult patients treated with palliative RT for chemotherapy refractory gingival myeloid sarcoma.

Frontiers in Oncology
05/10/2021
MicroRNA-383-5p Predicts Favorable Prognosis and Inhibits the Progression of Diffuse Large B-Cell Lymphoma

The present study aims to investigate the role of miR-383-5p in DLCBL. 

Oncology Letters
05/06/2021
Optimal Timing and Criteria of Interim PET in DLBCL: A Comparative Study of 1692 Patients

The aim of this study is to determine the optimal timing and response criteria for evaluating prognosis with I-PET in DLBCL. 

Blood Advances
05/04/2021
Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches—Focus on EZH2-Targeted Drugs

Epigenetic modifier gene mutations are common in patients with FL.

Current Oncology Reports
05/03/2021
Safety and Immunogenicity of One versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients With Cancer

This study examines the safety and immunogenicity of the BNT162b2 vaccine in patients with cancer.

The Lancet Oncology
04/27/2021
Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers

This study aims to compare patients with early oral cavity squamous cell carcinoma treated with traditional elective neck dissection with those managed by sentinel lymph node biopsy using...

Journal of Clinical Oncology
04/20/2021
Use of the Anti-Parasitic Drug Ivermectin to Treat Breast Cancer

Despite significant advances in the treatment of breast cancer, TNBC remains the most difficult subtype to treat.

Oncology Times - Latest Articles
05/05/2021
Freezing Breast Cancer to Death Avoids Surgery

In the US, cryoablation or freezing tissue to death is a primary treatment option for many cancers. But unlike in Europe, this nonsurgical approach is not approved for breast cancer in the US.

Medscape
05/10/2021
miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: An Axis Affected by BCR Inhibitors

miR-29 down-modulation in an intraclonal CLL subpopulation from immune niches allows for higher TRAF4 and increased CD40 responsiveness.

Blood
05/06/2021
MicroRNA-363-3p Promote the Development of Acute Myeloid Leukemia With RUNX1 Mutation by Targeting SPRYD4 and FNDC3B

This study aims to identify the key genes and microRNAs based on acute myeloid leukemia with RUNX1 mutation. 

Medicine
05/07/2021
A Clinical Transcriptome Approach to Patient Stratification and Therapy Selection in Acute Myeloid Leukemia

Study investigators develop and validate a clinical transcriptome-based assay for stratification of acute myeloid leukemia.

Nature Communications
04/30/2021
Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia

This study addresses NK cell maturation in bone marrow under three conditions: a normal developmental environment, during pre-leukemic state, and during leukemic transformation.

Frontiers in Immunology
04/27/2021
The Value of Complete Remission According to Positron Emission Tomography Prior to Autologous Stem Cell Transplantation in Lymphoma: A Population-Based Study Showing Improved Outcome

CAR T-cell and bispecific antibody therapies will likely necessitate a reconsideration of the role of ASCT in lymphoma. Patients who are likely to profit from ASCT need to be better identified.

BMC Cancer
05/04/2021
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma

The ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up for Follicular Lymphoma released in the late 2020 in accordance with the ESMO standard operating procedures for...

Hemasphere
04/21/2021
VTE Incidence in NSCLC Varies by Treatment Type

Venous thromboembolism rates among patients with advanced non-small cell lung cancer varied by treatment type, according to retrospective study results.

Healio
05/09/2021
Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR+, HER2- Advanced Breast Cancer Among Premenopausal or Perimenopausal Women

This study evaluates the cost-effectiveness of adding ribociclib to endocrine therapy for pre/perimenopausal women with HR+, HER2- advanced breast cancer from the US payer perspective.

Frontiers in Oncology
05/07/2021
Pediatric Cancer Survivors at Risk for Opioid Misuse

Survivors of childhood cancers are at increased risk for prescription opioid misuse compared with their peers, a review of a claims database revealed.

Medscape
05/06/2021
Silencing of PSMC2 Inhibits Development and Metastasis of Prostate Cancer Through Regulating Proliferation, Apoptosis and Migration

Here, expression of PSMC2 in tumor tissues or cells of prostate cancer is detected by qPCR, western blotting and immunohistochemical analysis.

Cancer Cell International
04/26/2021
Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies

The purpose of this study is to evaluate the impact of time to castration resistance in mHSPC patients on overall survival in the era of combination therapies for mHSPC.

Frontiers in Oncology
04/23/2021
Phase III ARIEL4 Confirms Rucaparib’s Benefit in BRCA-Mutated Relapsed Ovarian Cancer

In patients with BRCA-mutated, advanced, relapsed ovarian cancer, treatment with the PARP inhibitor rucaparib leads to a significant improvement in PFS compared with standard-of-care CT.

The ASCO Post
05/10/2021
Analysis of Autophagy-Related Signatures Identified Two Distinct Subtypes for Evaluating the Tumor Immune Microenvironment and Predicting Prognosis in Ovarian Cancer

This study constructs an autophagy-related prognostic indicator, and identifies two promising targets in ovarian cancer. 

Frontiers in Oncology
05/10/2021
Better Survival After Lumpectomy Plus RT vs Mastectomy

Overall survival and breast cancer–specific survival are consistently better for women with early breast cancer who are treated with BCS followed by RT compared to women who are treated with Mx...<

Medscape
05/10/2021
First-Line Pembrolizumab Plus Chemotherapy in PD-L1–Positive Locally Recurrent Triple-Negative Breast Cancer

The addition of pembrolizumab to CT improves PFS among previously untreated patients with locally recurrent inoperable or metastatic TNBC with a PD-L1 expression combined positive score ≥ 10.

The ASCO Post
05/10/2021
Effect of Lisocabtagene Maraleucel on HRQoL and Symptom Severity in Relapsed/Refractory Large B-Cell Lymphoma

HRQoL and symptom improvements across prespecified EORTC QLQ-C30 scales were clinically meaningful in a notable proportion of patients.

Blood Advances
04/27/2021
Effect of Oral Chemotherapy Management Program on Capecitabine Toxicity

This study finds that implementation of an oral CT management program is associated with reduced rates of any-grade and severe capecitabine toxicity, less frequent toxicity-related...

The ASCO Post
05/07/2021
Rankings of Most Common Cancers to Shift Over Next 20 Years

The next 20 years will see a big shift in cancer type rankings, researchers predict.

Medscape
04/14/2021
Comprehensive CRISPR-Cas9 Screens Identify Genetic Determinants of Drug Responsiveness in Multiple Myeloma

The introduction of new drugs in the past years has substantially improved outcome in multiple myeloma.

Blood Advances
05/05/2021
Superior Survival With Sintilimab in Squamous NSCLC

Second-line treatment with sintilimab improves survival, when compared with docetaxel, in patients with advanced/metastatic squamous non–small cell lung cancer in a phase 3 trial.

Medscape
05/04/2021
KRAS G12C Mutation with Dr Tetsuya Mitsudomi

This episode of Lung Cancer Considered covers recent promising results with new targeted agents for NSCLC harboring a KRAS G12C mutation. 

05/03/2021
No One Missed - Non-Small Cell Lung Cancer Biomarker Testing

Dr Jorge Gomez and Andrea Ferris discuss "No One Missed", a new campaign to raise awareness about comprehensive biomarker testing which can reveal vital information that can help identify the appropriate individualized...

05/03/2021
Breakthrough Therapies - ALK with Dr Ignatius Ou

Dr Sai-Hong Ignatius Ou shares his career growth and experience participating and leading breakthrough clinical trials on therapies to treat ALK positive patients with lung cancer. 

04/12/2021
RET Fusions in Lung Cancer with Dr Alex Drilon

Dr Alex Drilon discusses his career and work on RET fusions in lung cancer.

03/10/2021
WCLC 2020 Highlights and Wrap-Up

Together Dr Liu, Dr Duma and Dr Soo discuss key science, highlights, benefits and challenges of the virtual meeting.

02/10/2021
Target Therapies for Lung Cancer

Listen as Dr Matt-Amaral shares her insights into novel strategies that are evolving with genetic driver mutations and how immunotherapy is changing the way we treat metastatic disease patients.

01/10/2021
Single-Fraction Stereotactic Body Radiation Therapy Effective for Early Stage Lung Cancer

Dr Gregory Videtic, radiation oncologist at Cleveland Clinic Cancer Center, joins the Cancer Advances podcast to discuss the findings that were presented at the American Society for Radiation Oncology annual meeting.

12/10/2020